The DOI matches its Crossref record; 193 of the 193 references it cites were found in a registry or an index.
Combinational strategy for high-performance cancer chemotherapy
Abstract
The clinical outcomes of conventional mono-chemotherapy of cancers are usually far from satisfactory due to some issues such as tumor heterogeneity and resistance to chemotherapeutic drugs. With the increasing knowledge of molecular signal pathways and pathological mechanisms involved in the initiation and progression of cancers, collaborative strategies have been elaborated to optimize therapeutic outcomes. This review surveys the most recent advances in combination therapy including combination chemotherapy, chemotherapy plus gene therapy, chemotherapy plus phototherapy, as well as chemotherapy plus immunotherapy. Additionally, chemotherapy-involved multiple therapy that merges various therapeutic modalities is also presented. We try to elicit the rationales of applying these combinational formulations for cancer chemotherapy, which might provide new guidelines for high-performance cancer treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Toll-like receptor control of the adaptive immune responses
Iwasaki, A., & Medzhitov, R. (2004) · Nature Immunology · doi:10.1038/ni1112 · Cited by 4,193
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Upconversion Nanoparticles: Design, Nanochemistry, and Applications in Theranostics
Chen, G., Qiu, H., Prasad, P. N., & Chen, X. (2014) · Chemical Reviews · doi:10.1021/cr400425h · Cited by 2,699
The causes and consequences of genetic heterogeneity in cancer evolution
Burrell, R. A., McGranahan, N., Bartek, J., & Swanton, C. (2013) · Nature · doi:10.1038/nature12625 · Cited by 2,262
Delivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800
Overcoming the Achilles' heel of photodynamic therapy
Fan, W., Huang, P., & Chen, X. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00616g · Cited by 1,684
Muller, P. A. J., & Vousden, K. H. (2013) · Nature Cell Biology · doi:10.1038/ncb2641 · Cited by 1,647
Cited by
A Review on Nano-Based Drug Delivery System for Cancer Chemoimmunotherapy
Mu, W., Chu, Q., Liu, Y., & Zhang, N. (2020) · Nano-Micro Letters · doi:10.1007/s40820-020-00482-6 · Cited by 328
Controlling the biodistribution and clearance of nanomedicines
Cabral, H., Li, J., Miyata, K., & Kataoka, K. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00138-1 · Cited by 303
Status and Challenges of Plant-Anticancer Compounds in Cancer Treatment
Garcia-Oliveira, P., Otero, P., Pereira, A. G., Chamorro, F., Carpena, M., Echave, J., Fraga-Corral, M., Simal-Gandara, J., & Prieto, M. A. (2021) · Pharmaceuticals · doi:10.3390/ph14020157 · Cited by 303
NIR‐II Organic Nanotheranostics for Precision Oncotherapy
Dai, H., Wang, X., Shao, J., Wang, W., Mou, X., & Dong, X. (2021) · Small · doi:10.1002/smll.202102646 · Cited by 110
Recent advances in polymeric core–shell nanocarriers for targeted delivery of chemotherapeutic drugs
Yang, X., & Xie, Y. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121094 · Cited by 33
Metadata
- Authors
- Qin, S.-Y., Cheng, Y.-J., Lei, Q., Zhang, A.-Q., & Zhang, X.-Z.
- Venue
- Biomaterials
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 171
- Pages
- 178-197
- ISSN
- 0142-9612 (ISSN-L)
- OpenAlex
- W2802126705
- Cited by
- 301
- References
- 193
- FWCI
- 9.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combinational strategy for high-performance cancer chemotherapy. https://app.cochat.ai/papers/10.1016/j.biomaterials.2018.04.027
- The paper
- Qin, S.-Y., Cheng, Y.-J., Lei, Q., Zhang, A.-Q., & Zhang, X.-Z. (2018). Combinational strategy for high-performance cancer chemotherapy. Biomaterials. https://doi.org/10.1016/j.biomaterials.2018.04.027
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.